Skip to content

Trial Summary

Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer (ADELE): a randomised phase 2 trial.

Acronym:

ADELE

ACTRN/NCT /ethics:

N/A

Scientific title:

Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer (ADELE): a randomised phase 2 trial.

Sponsor / Cooperative group:

ANZGOG/NHMRC

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase II
Age Range-
Sex-
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Sid Selva
Recruitment StatusNot Yet Recruiting